Vergote I, Denys H, De Greve J, Gennigens C, Van De Vijver K, Kerger J, Vuylsteke P, Baurain J F
Department of Oncology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium.
Department of Medical Oncology, Ghent University Hospital, C. Heymanslaan 10, 9000 Ghent, Belgium.
Facts Views Vis Obgyn. 2020 Oct 8;12(3):227-239.
Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.
大多数卵巢癌患者直到晚期才被诊断出来,此时生存预后较差,治疗决策也颇具挑战性。卵巢癌女性患者的基本治疗方法包括尽可能进行肿瘤细胞减灭术以及适当的全身治疗(化疗、靶向治疗和抗血管生成药物)。在过去几年里,关于卵巢癌亚型和分期的组织学及分子特征的知识有了显著增加。这使得能够以患者个体化的方式开发和改进多种卵巢癌诊断与治疗方案。因此,治疗决策以患者和肿瘤的特征为指导,尤其是癌症亚型和疾病分期的分子特征。特别相关的是参与DNA修复的胚系和体细胞突变早期基因检测的进展以及靶向药物的临床开发。为了实施最佳的个体化医疗策略,在本文中,我们提出了一种针对比利时原发性和复发性卵巢癌患者的治疗方案算法,包括最近开发的靶向药物。